Targeted therapy for breast cancer

Keyphrases

• Estrogen Receptor 100%
• Breast Cancer 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• Triple-negative Breast Cancer 100%
• Targeted Therapy 100%
• Targeted Agents 66%
• Clinical Trials 33%
• Therapeutic Intervention 33%
• Breast Cancer Treatment 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• Phosphoinositide 3-kinase (PI3K) 33%
• Clinical Cohort 33%
• Progesterone Receptor 33%
• Protein Pathway 33%
• Heat Shock Proteins 33%
• Cell Cycle Regulation 33%
• Aromatase Inhibitors 33%
• Tumor Biology 33%
• MTOR Inhibitor 33%
• Everolimus 33%
• Acquired Resistance 33%
• New Agents 33%
• Heterogeneous Groups 33%
• Cancer Therapeutics 33%
• PARP Inhibitor (PARPi) 33%
• Hormone Receptor-positive 33%
• Inhibitor Resistant 33%
• Epigenetic Pathways 33%
• Advanced or Metastatic 33%
• HER2+ 33%

Medicine and Dentistry

• Breast Cancer 100%
• Targeted Therapy 100%
• Estrogen Receptor 75%
• Triple Negative Breast Cancer 75%
• Malignant Neoplasm 25%
• Clinical Trial 25%
• Aromatase Inhibitor 25%
• Cancer 25%
• Epidermal Growth Factor Receptor 2 25%
• Progesterone Receptor 25%
• Gamma Urogastrone 25%
• Phosphoinositide 3-Kinase 25%
• Tumor Biology 25%
• Mechanistic Target of Rapamycin 25%
• Everolimus 25%
• Mammalian Target of Rapamycin Inhibitor 25%
• Hormone Receptor 25%
• Cell Cycle Regulation 25%
• PARP Inhibitor 25%
• Heat Shock Protein 25%
• Diseases 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Estrogen Receptor 75%
• Triple Negative Breast Cancer 75%
• Malignant Neoplasm 25%
• Neoplasm 25%
• Clinical Trial 25%
• Phosphatidylinositol 3 Kinase 25%
• Mammalian Target of Rapamycin 25%
• Aromatase Inhibitor 25%
• Progesterone Receptor 25%
• Epidermal Growth Factor Receptor 2 25%
• Gamma Urogastrone 25%
• Hormone Receptor 25%
• Everolimus 25%
• Mammalian Target of Rapamycin Inhibitor 25%
• Heat Shock Protein 25%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 25%
• Diseases 25%